Pfizer CentreOne

Sterile injectables made with intelligent collaboration

Sterile injectables made with compelling science.

An altogether different approach to sterile injectables.



An altogether different kind of CDMO

Open dialogue. Successful delivery.

Welcome to Pfizer CentreOne. We strive to deliver on what we promise, which is surprisingly refreshing.

We're a global CDMO backed by Pfizer resources and a leader in sterile injectables. Working with our customers, we combine our technical and commercial knowledge with open dialogue to help solve your challenges, and scale with you every step of the journey.

An open and collaborative approach with Pfizer CentreOne

Our open and collaborative approach means we can offer you more efficient routes to market, high-quality sterile injectables and long-term supply assurance, so you always have what you need, when you need it. We've been helping our partners overcome many technical challenges for over 40 years. You can count on us to carefully guide your compound from development through to commercial manufacture. We're dedicated to being your dependable manufacturing partner, at the scale you need.

We're known for our expertise in:

- Complex biologics
- Controlled substances (II-IV)
- Lyophilization
- Sterile suspensions

More collaboration, better solutions.

Our sterile injectables manufacturing network includes sites in:

- Australia (Melbourne)
- China (Wuxi)
- Croatia (Zagreb)
- Spain (Algete)
- United States (Kalamazoo, Michigan; McPherson, Kansas; Rocky Mount, North Carolina)

We offer comprehensive regulatory submission support that has established approvals around the globe, including FDA (United States), EMA (European Union), ANVISA (Brazil) and PMDA (Japan).



- Development & manufacturing
- Technical transfer
- Formulation
- Scale-up/validation

- CMC preparation
- Final package
- Pre-approval inspection

- Drug to market
- Production efficiency studies

- Cold-chain management
- Supply/distribution
- Drug delivery expansion

Capabilities at a glance:

Manufacturing	Clinical Commercial
Services & processes	Aseptic fill-finish Terminal sterilization Lyophilization Combination products
Compounds	Biologics Small molecules Controlled substances (II-IV) Liposomal Cytotoxics (liquid) Vaccines (inactivated) Monobactam Sterile suspensions Potent drugs Hormones, steroids & prostaglandins
Other substances	Diluents
Container closure systems	Vials Syringes Ampoules Cartridges
Secondary packaging and global supply chain services	• Packaging capabilities include: bulk (bright stock), single-/multi-unit cartons, kitting and multi-lingual labelling and package inserts • Secondary packaging development, including customized kits • Serialization (track and trace) programs • Drug product storage and distribution: ambient (+15°C to +30°C), controlled room temperature (+15°C to +25°C), refrigerated (+2°C to +8°C), frozen (-15°C to -25°C) • Cold chain logistics • EU gateway services, including quality release support
Regulatory overview cGMP inspections	FDA, EMA, ANVISA, GCC, GCC-DR, Health Canada, Korean FDA, MHRA, NMPA, PMDA, Taiwanese MOH, TGA, Turkish MoH, AIFA, COFEPRIS, EAEU, MOITRF, Kazakhstan, Belarus

Discover how we're **altogether different**

Visit us at **www.pfizercentreone.com**



Pfizer CentreOne

www.pfizercentreone.com

PC1-19-0009/April2022-V4